You are here: Industry Insights > Junshi

News List

Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020 PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
Which Will Go Further? Innovent or Junshi? PharmaSources/Caicai
November 10, 2020
Junshi Biosciences was officially listed on the SSE STAR Market on July 15, with the stock code: 688180 and the issue price at RMB55.5/share; the opening price surged by nearly 200%, with the market value peaking at more than RMB150 billion.
Junshi Biosciences Sinks After US Halts Chinese Firm’s Covid-19 Antibody Therapy firstwordpharma
June 29, 2021
Junshi Biosciences' shares fell as much as 4% after the drugmaker confirmed that distribution of its antibody combination therapy for COVID-19, developed with Eli Lilly, has been suspended in the US, as reported Yicai Global on Monday.
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy americanpharmaceuticalreview
March 26, 2021
Eucure Biopharma, a subsidiary of Biocytogen, announced its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection (TUOYI®), has demonstrated encouraging anti-tumor activity in a ...
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1 prnasia
March 23, 2021
Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection ...
NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein contractpharma
March 10, 2021
JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β.
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein prnasia
March 08, 2021
Recently, CMAB Biopharma (Suzhou) Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products ...
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab prnasia
February 04, 2021
Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®) ...